Semaglutide A1C Reduction: The Diabetes Trial Data
GLP-1 Diabetes
1.8% A1C reduction
In the SUSTAIN 7 trial, semaglutide 1.0 mg reduced HbA1c by 1.8 percentage points, outperforming the comparator GLP-1 agonist dulaglutide 1.5 mg, which achieved 1.4 percentage points.
Pratley et al., The Lancet Diabetes & Endocrinology, 2018
Pratley et al., The Lancet Diabetes & Endocrinology, 2018
View as imageSemaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for type 2 diabetes as Ozempic (subcutaneous injection, weekly) and Rybelsus (oral tablet, daily). Its A1C-lowering effects were established across two parallel clinical trial programs: SUSTAIN (subcutaneous, 10 trials) and PIONEER (oral, 10 trials), enrolling over 17,000 patients combined. The consistent finding across both programs is that semaglutide reduces A1C more effectively than every active comparator tested, including other GLP-1 agonists, insulin glargine, sitagliptin, and metformin. This article reviews the A1C data from both programs, the head-to-head comparisons, the cardiovascular and safety outcomes, and the practical factors that determine which patients benefit most.
Key Takeaways
- Subcutaneous semaglutide 1.0 mg reduced A1C by 1.5-1.8 percentage points across SUSTAIN 1-7, consistently outperforming all active comparators at 30-56 weeks (Aroda et al., 2019).[1]
- Oral semaglutide 14 mg reduced A1C by 1.0-1.4 percentage points across PIONEER 1-10, with a pooled analysis confirming patient-reported quality of life improvements alongside glycemic control (Rudofsky et al., 2025).[9]
- Semaglutide reduced cardiovascular events (MACE) by 26% versus placebo in SUSTAIN 6, a benefit that persisted regardless of metformin co-treatment (Husain et al., 2022).[5]
- Real-world sustained GLP-1 agonist use improved glycemic control and reduced all-cause mortality compared to discontinuation in a Danish cohort (Sorensen et al., 2026).[15]
- The A1C reduction was independent of baseline kidney function, with semaglutide showing consistent efficacy in patients with moderate renal impairment (PIONEER 5, Mosenzon et al., 2019).[6]
- Gastrointestinal side effects (nausea, vomiting, diarrhea) were the most common adverse events, occurring in 15-20% of patients across both programs, with most events mild to moderate and declining over time (Aroda et al., 2023).[7]
The SUSTAIN program: subcutaneous semaglutide
The SUSTAIN (Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes) program comprised 10 Phase III trials evaluating once-weekly subcutaneous semaglutide at doses of 0.5 mg and 1.0 mg (later 2.0 mg in SUSTAIN FORTE). The trials systematically compared semaglutide against placebo and every major diabetes drug class.
Aroda et al. (2019) published the comprehensive comparison of SUSTAIN 1-7, establishing the following A1C reductions from baseline:[1]
| Trial | Comparator | Duration | Semaglutide 0.5 mg | Semaglutide 1.0 mg | Comparator Result |
|---|---|---|---|---|---|
| SUSTAIN 1 | Placebo | 30 weeks | -1.45% | -1.55% | -0.02% |
| SUSTAIN 2 | Sitagliptin 100 mg | 56 weeks | -1.3% | -1.6% | -0.5% |
| SUSTAIN 3 | Exenatide ER 2 mg | 56 weeks | -- | -1.5% | -0.9% |
| SUSTAIN 4 | Insulin glargine | 30 weeks | -1.2% | -1.6% | -0.8% |
| SUSTAIN 5 | Placebo (add-on to basal insulin) | 30 weeks | -1.4% | -1.8% | -0.1% |
| SUSTAIN 7 | Dulaglutide 0.75/1.5 mg | 40 weeks | -1.5% | -1.8% | -1.1/-1.4% |
Several patterns emerge from these data. First, semaglutide 1.0 mg consistently reduced A1C by 1.5-1.8 percentage points regardless of the comparator, the background therapy, or the disease stage. Second, the 1.0 mg dose outperformed the 0.5 mg dose by approximately 0.2-0.4 percentage points. Third, semaglutide produced statistically superior A1C reductions versus every active comparator tested: sitagliptin (by approximately 1.1 percentage points), exenatide (by 0.6 points), insulin glargine (by 0.8 points), and dulaglutide (by 0.4 points at the highest comparator dose).
SUSTAIN FORTE later tested 2.0 mg versus 1.0 mg in patients with inadequate control on 1.0 mg (mean baseline A1C of 8.9%), showing an additional 0.18 percentage point reduction with the higher dose (estimated treatment difference -0.18%, 95% CI -0.36 to -0.01; P = 0.038). The clinical significance of this incremental difference is debatable: some patients with A1C values stubbornly above target on 1.0 mg may benefit from dose escalation, but the modest improvement must be weighed against potentially higher GI event rates at the 2.0 mg dose.
SUSTAIN 6 was the cardiovascular outcomes trial, designed not primarily to measure A1C reduction but to demonstrate cardiovascular safety (a regulatory requirement for diabetes drugs since 2008). The trial randomized 3,297 patients at high cardiovascular risk for a median 2.1 years. A1C reductions of 1.1 percentage points (0.5 mg) and 1.4 percentage points (1.0 mg) versus placebo were sustained over the longer treatment duration, demonstrating that semaglutide's glycemic efficacy is maintained over two years of use.
The PIONEER program: oral semaglutide
The PIONEER (Peptide InnOvatioN for Early diabEtes tReatment) program tested oral semaglutide (Rybelsus) at 3, 7, and 14 mg daily doses. Oral delivery of a GLP-1 peptide was considered pharmacologically implausible until Novo Nordisk co-formulated semaglutide with the absorption enhancer SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate), which protects the peptide from gastric degradation and facilitates transepithelial absorption in the stomach.
The oral formulation achieved lower absolute A1C reductions than subcutaneous semaglutide (approximately 1.0-1.4% for the 14 mg dose versus 1.5-1.8% for the 1.0 mg injection), reflecting the lower bioavailability of oral delivery. Oral semaglutide bioavailability is approximately 1%, meaning only about 1% of the ingested dose reaches systemic circulation, compared to nearly 90% for subcutaneous injection.
Rudofsky et al. (2025) published a pooled analysis of all seven PIONEER REAL studies (real-world observational data from multiple countries), confirming that oral semaglutide's A1C-lowering effects observed in clinical trials translated to routine clinical practice. The pooled data showed consistent glycemic improvements alongside patient-reported quality of life benefits, addressing the question of whether trial results generalize to the diverse populations seen in real clinical settings.[9]
Mosenzon et al. (2019) demonstrated in PIONEER 5 that oral semaglutide maintained its glycemic efficacy in patients with moderate renal impairment (eGFR 30-59 mL/min), a population that often requires dose adjustments with other diabetes medications. A1C reduction with oral semaglutide 14 mg was 1.0 percentage point versus 0.2 for placebo, with no dose adjustment required.[6]
Head-to-head: semaglutide versus other GLP-1 agonists
The most clinically relevant comparisons from the SUSTAIN program are the head-to-head trials against other GLP-1 receptor agonists, since these are the drugs most likely to be considered as alternatives.
Versus exenatide (SUSTAIN 3). Semaglutide 1.0 mg reduced A1C by 1.5% versus 0.9% for exenatide extended-release 2.0 mg over 56 weeks. This 0.6 percentage point advantage was statistically significant and clinically meaningful.
Versus dulaglutide (SUSTAIN 7). This was the most closely matched comparison. Semaglutide 1.0 mg achieved -1.8% versus -1.4% for dulaglutide 1.5 mg. At the lower doses, semaglutide 0.5 mg achieved -1.5% versus -1.1% for dulaglutide 0.75 mg. Semaglutide showed superior A1C reduction at both dose levels.
Versus liraglutide (SUSTAIN 10). Semaglutide 1.0 mg reduced A1C by 1.7% versus 1.0% for liraglutide 1.2 mg, a 0.7 percentage point advantage. Liraglutide was tested at its diabetes dose (1.2 mg), not the obesity dose (3.0 mg).
Ji et al. (2024) examined how baseline characteristics influenced semaglutide's efficacy in a predominantly Asian population. Higher baseline A1C, shorter diabetes duration, and no prior insulin use predicted greater A1C reductions, though semaglutide remained effective across all subgroups analyzed.[10]
Cardiovascular outcomes: beyond A1C
A1C reduction alone does not capture the full clinical value of a diabetes medication. SUSTAIN 6 (the cardiovascular outcomes trial) randomized 3,297 patients to semaglutide versus placebo for a median 2.1 years. The primary outcome, major adverse cardiovascular events (MACE: cardiovascular death, nonfatal myocardial infarction, nonfatal stroke), occurred in 6.6% of semaglutide patients versus 8.9% of placebo patients, a 26% relative risk reduction (HR 0.74, 95% CI 0.58-0.95).
Husain et al. (2020) performed a combined post hoc analysis of SUSTAIN 6 and PIONEER 6 (the oral semaglutide CV trial), showing that semaglutide reduced cardiovascular events across varying levels of cardiovascular risk. The benefit was not limited to patients with established cardiovascular disease; those with cardiovascular risk factors alone also showed a trend toward reduced events.[3][4]
Husain et al. (2022) further demonstrated that semaglutide's cardiovascular benefit was independent of metformin co-treatment. Patients taking semaglutide with metformin and those taking semaglutide without metformin showed similar cardiovascular event reductions, eliminating the hypothesis that metformin was a confounding factor in the cardiovascular outcomes.[5]
Mosenzon et al. (2022) analyzed the impact of semaglutide on high-sensitivity C-reactive protein (hsCRP), a marker of systemic inflammation and cardiovascular risk, across both SUSTAIN and PIONEER programs. Semaglutide consistently reduced hsCRP levels, suggesting an anti-inflammatory mechanism that may contribute to cardiovascular protection beyond glycemic control.[8]
For a comprehensive review of semaglutide's cardiovascular trial data, see our companion article.
Kidney outcomes
Tuttle et al. (2024) analyzed kidney disease outcomes by KDIGO risk category in SUSTAIN 6. Semaglutide reduced the composite kidney endpoint (new or worsening nephropathy) compared to placebo, with effects observed across baseline kidney risk categories. The kidney benefit appeared driven primarily by reductions in new-onset macroalbuminuria rather than slowing of eGFR decline.[11]
Zhou et al. (2025) extended this analysis, examining cardiorenal outcomes by prior cardiovascular disease status and baseline BMI. Semaglutide's cardiorenal benefits were consistent across BMI categories, countering the concern that kidney protection might be driven entirely by weight loss.[13]
Safety profile across both programs
Aroda et al. (2023) published the definitive safety analysis spanning both SUSTAIN and PIONEER Phase IIIa programs. The most common adverse events were gastrointestinal: nausea (15-20% of patients), diarrhea (8-12%), and vomiting (5-10%). Most GI events were mild to moderate, occurred during the dose escalation phase, and declined in frequency after the first 8-12 weeks of treatment.[7]
Discontinuation rates due to adverse events were 6-10% for semaglutide across the programs, compared to 2-4% for placebo. The higher-dose formulations (semaglutide 1.0 mg subcutaneous, 14 mg oral) had modestly higher GI event rates than the lower doses.
Bain et al. (2025) examined cardiovascular, metabolic, and safety outcomes by baseline age in a post hoc analysis of SUSTAIN 6 and PIONEER 6. Older patients (65 years and above) showed similar A1C reductions and cardiovascular benefits as younger patients, with no increase in serious adverse events, supporting semaglutide's use in the elderly population where diabetes burden is highest.[12]
Diabetic retinopathy was one safety signal that emerged from SUSTAIN 6: early worsening of retinopathy occurred more frequently with semaglutide (3.0%) than placebo (1.8%). Subsequent analysis suggested this was related to the magnitude and speed of A1C reduction rather than a direct semaglutide effect: rapid glycemic improvement has been associated with temporary retinopathy worsening across multiple drug classes, including insulin. Patients with pre-existing retinopathy and very high baseline A1C values (where the A1C reduction would be most dramatic) appeared most susceptible. This finding has led to clinical guidance suggesting baseline eye examinations before initiating semaglutide in patients with known retinopathy and monitoring during the first year of treatment.
Drug interactions with semaglutide are primarily related to its effect on gastric emptying. Because semaglutide slows the rate at which the stomach empties, it can alter the absorption kinetics of co-administered oral medications. This effect is most clinically relevant for drugs with narrow therapeutic windows (such as warfarin or levothyroxine) and for oral contraceptives, where delayed absorption could theoretically affect efficacy. Oral semaglutide's SNAC absorption enhancer adds another consideration: the requirement for an empty stomach means patients must coordinate oral semaglutide timing with other medications, potentially complicating polypharmacy regimens common in type 2 diabetes patients.
Real-world evidence
Clinical trials enroll selected populations under controlled conditions. Real-world evidence addresses whether trial results translate to routine practice. The PIONEER REAL program collected observational data from seven countries (Japan, Sweden, UK, Saudi Arabia, Spain, India, Italy), consistently showing that oral semaglutide reduced A1C and body weight in real clinical settings.[9]
Sorensen et al. (2026) provided the strongest real-world evidence to date. In a Danish cohort, sustained GLP-1 receptor agonist treatment improved glycemic control and reduced all-cause mortality compared to treatment discontinuation. This finding is significant because it suggests that the cardiovascular and mortality benefits observed in trials like SUSTAIN 6 extend to broader populations receiving standard care over longer time horizons.[15]
Verma et al. (2021) applied the cardiovascular disease criteria from the REWIND trial (which tested dulaglutide) to the SUSTAIN 6 and PIONEER 6 datasets, finding that semaglutide's cardiovascular benefits were consistent when assessed using different trial-design criteria, strengthening confidence that the effect is real rather than an artifact of patient selection.[14]
Leiter et al. (2019) performed a gender-based post hoc analysis of SUSTAIN 6, finding that cardiovascular risk reduction was consistent between men and women. This is relevant because women are underrepresented in many cardiovascular outcome trials, and sex-specific differences in GLP-1 agonist response have been a concern. The analysis showed similar hazard ratios for MACE in both sexes, though the confidence intervals were wider in women due to lower event rates.[2]
The expanding evidence base for semaglutide's non-glycemic benefits, including potential effects on addictive behavior and brain reward pathways, has raised the possibility that GLP-1 agonists may eventually be prescribed for indications far beyond diabetes. For now, the A1C data from SUSTAIN and PIONEER remains the foundation on which all other semaglutide applications are built.
What determines who benefits most
Not all patients achieve the same A1C reduction with semaglutide. Ji et al. (2024) identified several predictors of greater glycemic response: higher baseline A1C (patients starting at 9% or above experienced larger absolute reductions than those starting at 7.5%), shorter diabetes duration (suggesting more preserved beta-cell function), and no prior insulin use.[10]
These predictors have practical implications. A patient with recently diagnosed type 2 diabetes and an A1C of 9.5% might expect a 2+ percentage point reduction, potentially reaching an A1C below 7%. A patient with 15 years of diabetes, significant beta-cell depletion, and an A1C of 8.0% might achieve a more modest 1.0 percentage point reduction. Both responses are clinically valuable, but setting realistic expectations matters for adherence.
The oral formulation introduces an additional variable: the requirement to take Rybelsus on an empty stomach with no more than 4 ounces (120 mL) of plain water, then wait at least 30 minutes before eating, drinking, or taking other oral medications. Non-adherence to these dosing conditions reduces absorption and may explain why some patients in real-world settings achieve less A1C reduction than trial participants, who received extensive dosing education. The cost-effectiveness of oral versus injectable semaglutide depends in part on this adherence factor.
The question of whether semaglutide or any GLP-1 agonist can achieve diabetes remission (sustained A1C below 6.5% off medication) is addressed in our companion article.
Semaglutide versus tirzepatide
The most significant competitive development since SUSTAIN is the arrival of tirzepatide, a dual GLP-1/GIP receptor agonist that has shown numerically greater A1C reductions in its SURPASS trial program. In SURPASS-2, tirzepatide 15 mg reduced A1C by 2.3 percentage points compared to semaglutide 1.0 mg at 2.0 percentage points over 40 weeks. While this was not a head-to-head comparison using the 2.0 mg semaglutide dose, it established tirzepatide as a potential successor in glycemic efficacy. Whether the additional A1C reduction translates to meaningful clinical differences in long-term outcomes (cardiovascular events, kidney disease, mortality) remains to be determined by ongoing outcome trials.
The weight loss dimension
A1C reduction does not occur in isolation with semaglutide. Across the SUSTAIN program, patients lost an average of 3.6-6.1 kg with semaglutide 1.0 mg over trial durations of 30-56 weeks. Weight loss and glycemic improvement are mechanistically linked: GLP-1 agonists reduce appetite through hypothalamic signaling, slow gastric emptying, and improve insulin sensitivity, all of which contribute to both lower blood glucose and reduced body weight. However, post hoc analyses have consistently shown that semaglutide's A1C reduction is not fully explained by weight loss alone: patients who lost minimal weight still showed significant glycemic improvement, confirming direct effects on beta-cell function and hepatic glucose output.
The weight loss effect is clinically meaningful in a population where approximately 90% of type 2 diabetes patients are overweight or obese. Weight loss of 5% or more has independent cardiovascular and metabolic benefits, and many patients on semaglutide achieve this threshold. The relationship between semaglutide's weight effects and muscle mass preservation, particularly in older adults, is an active area of investigation.
The Bottom Line
Semaglutide reduces A1C by 1.5-1.8 percentage points as a subcutaneous injection (SUSTAIN program) and 1.0-1.4 percentage points as an oral tablet (PIONEER program), consistently outperforming all active comparators in head-to-head trials. Beyond glycemic control, SUSTAIN 6 demonstrated a 26% reduction in major cardiovascular events, and post hoc analyses confirmed benefits for kidney outcomes, inflammatory markers, and all-cause mortality in real-world settings. Gastrointestinal side effects are the primary tolerability concern. Tirzepatide has emerged as a competitor with potentially greater A1C reductions, though long-term outcome data is still maturing.